

Pharmacokinetic-guided Dosing of Emicizumab

NCT06320626

Status	RECRUITING
Phase	Phase 4
Sponsor	Kathelijn Fischer
Enrollment	95 participants

Key Eligibility Criteria

Inclusion (8)

- Confirmed diagnosis of congenital haemophilia A, with a baseline endogenous FVIII of <6 IU/ml
- Aged > 1 year at inclusion (inclusion of children 1-16 years after favourable interim-analysis see protocol)
- Receiving conventional dosing of emicizumab (6 mg/kg/4 weeks with varying intervals) for a duration of at least 12 months prior to inclusion;
- Having good bleeding control, defined as:
 - i No spontaneous joint/muscle bleeds in the previous 6 months AND ii A maximum of two treated (traumatic) bleeds in the previous 6 months.

... and 3 more (see full listing online)

Exclusion (1)

- Acquired haemophilia A

Locations (8 total)

Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Maastricht University Medical Center, Maastricht, Limburg, Netherlands
Amsterdam University Medical Center, Amsterdam, North Holland, Netherlands
... and 5 more locations